HOME > Investor Relations > Financial Results Highlights > New Drug Pipeline

New Drug Pipeline

New Drug Development

Taisho Pharmaceutical has positioned the four therapeutic areas of infectious diseases, orthopedic disorders, central nervous system, and metabolic diseases as its priority fields for research and development (R&D). In each of these fields, Taisho Pharmaceutical aims to discover innovative drugs that will pave the way for future growth.

Priority fields (infectious diseases/orthopedic disorders/CNS diseases/metabolic diseases)

In Japan, TS-152 for the planned indication of rheumatoid arthritis has entered Phase 3, while TS-142 for the planned indication of insomnia has entered Phase 2. Outside Japan, drugs mainly in the domain of psychiatric disorders, such as the TS-121 and the TS-134, are being developed. To create a number of new drugs chiefly in key domains amid intensifying competition for new drug creation, we work with outside research institutes and with domestic and overseas businesses to carry out research and development in an effort to enrich the pipeline (or the lineup of developed products).

New Drug Pipeline

As of February 14, 2020

In Japan

Phase3
Name Application Development with
TS-152*
(Injection)
Rheumatoid arthritis In-license
Phase2
Name Application Development with
TS-142
(Oral)
Insomnia In-house


Overseas

Phase2
Name Target disease Development with
TS-121
(Oral)
Depression In-house
Phase1
Name Target disease Development with
TS-134
(Oral)
Schizophrenia In-house
TS-161
(Oral)
Depression In-house

*TS-152: Generic name:Ozoralizumab